INDIGO Biosciences, Inc. was founded in 2005 in State College, PA. It remains a privately held biosciences company offering products and services focused on nuclear receptors, which comprise a major class of therapeutic drug targets. The Company's two founders, Dr. Jack Vanden Heuvel and Dr. Blake Peterson, leveraged their collective expertise's in nuclear receptor biology, toxicology, medicinal c
hemistry and molecular biology to establish the core platform technology of The Company. INDIGO Biosciences' original focus was that of a traditional contract research organization, namely, to provide custom services for the screening of small molecule compounds against functional human and non-human nuclear receptors. Over the years, The Company has demonstrated success in providing quality screening services to clients within the pharmaceutical, biotechnology, food, agriculture and nutriceutical industries, government research agencies, as well as to academic researchers.
